Search

Home > The Bio Report > Company Seeks to Prove Marine-Derived Alzheimer's Drug Is No Fish Story
Podcast: The Bio Report
Episode:

Company Seeks to Prove Marine-Derived Alzheimer's Drug Is No Fish Story
Category: Business
Duration: 00:43:28
Publish Date: 2019-03-07 13:45:37
Description: Neurotrope is developing its experimental therapy bryostatin as a potential treatment for Alzheimer’s disease and other neurodegenerative conditions. The company believes the drug has multiple mechanisms of action and can stimulate synaptic growth factors to repair damaged synapses, form new ones, and prevent neuronal death. The company, though, found itself in a controversy over the way it characterized results from a phase 2 study of the drug in 2017. It is now conducting a second phase 2 study of the drug in the hopes of demonstrating meaningful benefits for patients. We spoke to Daniel Alkon, chief scientific officer of Neurotrope, about bryostatin, the controversy over the way it reported its previous results, and the path forward for the drug.
Total Play: 0

Some more Podcasts by Levine Media Group

600+ Episodes
The Bio Repo ..